In the Media
Are you looking for the latest media coverage of the BioMed X Institute, its research projects and people behind the innovation model? Here you will find the latest clippings – hot off the press!
Visit: AWS and pharma heavyweights join forces on AI-based drug discovery lab
AWS and pharma heavyweights join forces on AI-based drug discovery lab
Medical Design Sourcing
The goal of using AI to transform drug discovery and development may not be novel. But a recent alliance is unique in both the stature of companies belonging to it and its choice of an innovation model.
Visit: New innovation lab brings together pharma, biotech giants for AI therapeutics
New innovation lab brings together pharma, biotech giants for AI therapeutics
Times of Israel
Pfizer, Merck, Teva, Amazon form consortium that runs AION Labs, an Israeli facility that will focus on harnessing artificial intelligence in drug development
Visit: Big Pharma companies join hands with Amazon on new Israel-based AI incubator
Big Pharma companies join hands with Amazon on new Israel-based AI incubator
Endpoints News
What do Merck, Pfizer, AstraZeneca and Teva have in common with Amazon? As of Wednesday, they’re all joining forces with the Israel Biotech Fund to launch a new incubator for startups walking the line between AI and drug development — and they’re gearing up to make some big investments.
Visit: Eine Gemeinschaft der Willigen – Standortakteure aus Heidelberg im Gespräch
Eine Gemeinschaft der Willigen – Standortakteure aus Heidelberg im Gespräch
GoingPublic.de
Die Plattform Life Sciences führte eine Gesprächsrunde mit den wichtigen Vertretern dieser neuen Entwicklungen in der Rhein-Neckar-Region. Unter dem Fokusthema „Translation“ haben sich dazu hybrid getroffen: Dr. Julia Schaft (BioRN), Dr. Christian Tidona (BioMed X), Dr. Johannes Frühauf (BioLabs, LabCentral), Dr. Siegfried Bialojan (ehemaliger EY-Experte Life Sciences), Dr. Thomas Hanke (Evotec), Dr. Friedrich Reinhard (Evotec; „Expert in Residence“ beLAB2122 in…
Visit: Wie in Deutschland mehr Unternehmen wie BioNTech entstehen können
Wie in Deutschland mehr Unternehmen wie BioNTech entstehen können
Frankfurter Allgemeine Zeitung
Der Impfstoffhersteller BioNTech ist ein glanzvolles Beispiel für eine Ausgründung aus der Hochschule. In Deutschland wird viel geforscht, aber kaum gegründet. Wie kann das öfter gelingen?
Visit: BioMed X and Janssen Start Up Research Programs in Autoimmunity and Drug Delivery
BioMed X and Janssen Start Up Research Programs in Autoimmunity and Drug Delivery
BioPharm
BioMed X has partnered with Janssen to start two new research programs for autoimmune diseases and drug delivery.
Visit: Professionelle Translation in Heidelberg – Das BioMed X Institut
Professionelle Translation in Heidelberg – Das BioMed X Institut
Deutsche Biotechnologietage 2021
rotz des technologischen Fortschritts in der medizinischen Grundlagenforschung und des stetig wachsenden Wissens über menschliche Krankheiten, ist die Translation von Forschungsergebnissen in therapeutische Fortschritte immer noch ineffizient.
Visit: BioMed X, Janssen Begin Autoimmunity and Drug Delivery Research
BioMed X, Janssen Begin Autoimmunity and Drug Delivery Research
Pharma Advancement
German independent research institute BioMed X has initiated two new research projects with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The collaboration aims to address two challenging new research areas.
Visit: BioMed X, Janssen Begin Autoimmunity and Drug Delivery Research
BioMed X, Janssen Begin Autoimmunity and Drug Delivery Research
Contract Pharma
New research groups, PTA and TMI, aim to combat chronic inflammatory diseases and develop oral delivery of macromolar therapeutics.
Visit: BioMed X Institute to launch autoimmunity and drug delivery research programs
BioMed X Institute to launch autoimmunity and drug delivery research programs
BioSpectrum Asia Edition
New research groups in Heidelberg to examine protective tissue factors in autoimmune diseases and the translocation of complex macromolecules across the intestinal epithelial barrier in collaboration with Janssen.
Visit: BioMed X Institute Today Announces Two New Research Groups in Autoimmunity and Drug Delivery in Collaboration with Janssen
BioMed X Institute Today Announces Two New Research Groups in Autoimmunity and Drug Delivery in Collaboration with Janssen
Pharmiweb
BioMed X Institute to start two new research programs in the field of autoimmune diseases and drug delivery. New research groups in Heidelberg to examine protective tissue factors in autoimmune diseases and the translocation of complex macromolecules across the intestinal epithelial barrier.
Visit: BioMed X Institute to launch autoimmunity and drug delivery research programs
BioMed X Institute to launch autoimmunity and drug delivery research programs
BioSpectrum
New research groups in Heidelberg to examine protective tissue factors in autoimmune diseases and the translocation of complex macromolecules across the intestinal epithelial barrier in collaboration with Janssen
Visit: BioMed X to research autoimmune diseases and drug delivery with Janssen
BioMed X to research autoimmune diseases and drug delivery with Janssen
Pharmafile
BioMed X Institute is to start two new research programs in the field of autoimmune diseases and drug delivery in collaboration with Janssen.
Visit: Global Roundup: BioMed X, Merck KGaA Expand Oncology Collaboration
Global Roundup: BioMed X, Merck KGaA Expand Oncology Collaboration
BioSpace
Germany-based BioMed X Institute expanded its collaboration with Merck KGaA, Darmstadt, Germany to include a total of eight research programs in the field of DNA damage response and RNA splicing.
Visit: BioMed X expands research partnership with Merck KGaA
BioMed X expands research partnership with Merck KGaA
Pharmaceutical Commerce
BioMed X, an independent research institute, revealed the start of its eighth joint research program with Merck KGaA, Darmstadt, Germany. The new program will dive into the role of extrachromosomal DNA in cancer and it will complement the research of two ongoing oncology programs at BioMed X in the fields of DNA damage response and RNA splicing.
Visit: BioMed X Expands Collaboration with Merck
BioMed X Expands Collaboration with Merck
Contract Pharma
BioMed X, an independent research institute, has initiated its eighth joint research program with Merck KGaA, Darmstadt, Germany.
Visit: BioMed X and Merck launch new Oncology research programme
BioMed X and Merck launch new Oncology research programme
Pharmafile
BioMed X and Merck have launched a new joint research programme in oncology.
Visit: Merck KGaA and BioMed X launch new joint cancer research programme
Merck KGaA and BioMed X launch new joint cancer research programme
PharmaTimes online
German pharma company Merck KGaA has announced a new partnership with BioMed X, an independent research institute located at the University of Heidelberg in Germany, in the area of oncology.
Visit: BioMed X and Merck launch oncology research programme
BioMed X and Merck launch oncology research programme
Manufacturing Chemist
The key aim of the project will be to generate a comprehensive atlas of extrachromosomal DNA in human cancer tissues.
Visit: BioMed X and Merck KGaA, Darmstadt, Germany launch new research program in oncology
BioMed X and Merck KGaA, Darmstadt, Germany launch new research program in oncology
1st Oncology
On July 5, 2021 BioMed X, a leading independent research institute, reported the start of its eighth joint research program with Merck KGaA, Darmstadt, Germany.
Visit: BioMed X and Merck Extend Collaboration to Advance Oncology an Autoimmunity Research
BioMed X and Merck Extend Collaboration to Advance Oncology an Autoimmunity Research
Pharma Tech Outlook
Merck will support up to six different research groups at Heidelberg’s BioMed X Institute over the next six years.